Adjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: Role of CEA and CA 19-9

Anticancer Research

Volumn 25, Issue 3 A, 2005, Pages 1787-1793

  Weissenberger, Christian ^a,b   Von Plehn, Georg ^a   Otto, Florian ^a   Barke, Annette ^a   Momm, Felix ^a   Geissler, Michael ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Division of Radiotherapy   (Germany)

Author keywords

CA 19 9; CEA; Overall survival; Prognostic factor; Rectal carcinoma; Tumor marker

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; LACTATE DEHYDROGENASE; MITOMYCIN C; MYC PROTEIN; PROTEIN BCL 2;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE REGIMEN; EVALUATION; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM ANTERIOR RESECTION; RECTUM CARCINOMA; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 21244495259     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Saltz LB and Minsky B: Adjuvant therapy of cancers of the colon and rectum. Surg Clin North Am 82: 1035-1058, 2002.
2. Kachnic LA and Willett CG: Radiation therapy in the management of rectal cancer. Curr Opin Oncol 13: 300-306, 2001.
3. Sauer R: Adjuvant and neoadjuvant radiotherapy and concurrent radiochemotherapy for rectal cancer. Pathol Oncol Res 8: 7-17, 2002.
4. Gold P and Goldenberg N: The carcinoembryonic antigen (CEA): past, present, and future. McGill J Med 3: 66, 1997.
5. Castells A, Bessa X, Daniels M, Ascaso C, Lacy AM, Garcia-Valdecasas JC, Gargallo L, Novell F, Astudillo E, Filella X and Pique JM: Value of postoperative surveillance after radical surgery for colorectal cancer: results of a cohort study. Dis Colon Rectum 41: 714-723, 1998.
6. Welch CE and Malt RA: Abdominal surgery (second of three parts). N Engl J Med 308: 685-695, 1983.
7. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
8. Peto R and Peto J: Asymptocally efficient rank invariant test procedures. J R Stat Soc A 135: 185-206, 1972.
9. Cox DR: Regression models and life tables. J R Stat Soc B 34: 187-220, 1972.
10. Nakayama T, Watanabe M, Teramoto T and Kitajima M: Slope analysis of CA19-9 and CEA for predicting recurrence in colorectal cancer patients. Anticancer Res 17: 1379-1382, 1997.
11. Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Pahl H and Fateh-Moghadam A: Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma. Anticancer Res 17: 2935-2938, 1997.
12. Filella X, Molina R, Pique JM, Grau JJ, Garcia-Valdecasas JC, Biete A, Novell F, Astudillo E, Bordas JM and Campo E: CEA as a prognostic factor in colorectal cancer. Anticancer Res 14: 705-708, 1994.
13. Nelson RL: The usefulness of carcinoembryonic antigen in postoperative colorectal cancer patients. Dis Colon Rectum 40: 866-867, 1997.
14. Dawson LA, Franssen E and Davey P: Postoperative borderline elevated CEA predicts for earlier relapse in patients with rectal cancer receiving adjuvant postoperative therapy. Cancer J Sci Am 5: 374-379, 1999.
15. Wang WS, Lin JK, Chiou TJ, Liu JH, Fan FS, Yen CC, Lin TC, Jiang JK, Yang SH, Wang HS and Chen PM: Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience. Jpn J Clin Oncol 30: 12-16, 2000.
16. Fucini C, Tommasi MS, Cardona G, Malatantis G, Panichi S and Bettini U: Limitations of CEA monitoring as a guide to second-look surgery in colorectal cancer follow-up. Tumori 69: 359-364, 1983.
17. Behbehani AI, Al Sayer H, Farghaly M, Kanawati N, Mathew A, al Bader A and van Dalen A: Prognostic significance of CEA and CA 19-9 in colorectal cancer in Kuwait. Int J Biol Markers 15: 51-55, 2000.
18. Lee YT: Local and regional recurrence of carcinoma of the colon and rectum: II. Factors relating to operative technique. Surg Oncol 5: 1-13, 1996.
19. Myerson RJ, Michalski JM, King ML, Birnbaum E, Fleshman J, Fry R, Kodner I, Lacey D and Lockett MA: Adjuvant radiation therapy for rectal carcinoma: predictors of outcome. Int J Radiat Oncol Biol Phys 32: 41-50, 1995.
20. Weissenberger C, Fiebig HH, Lutterbach J, Barke A, Momm F, Muller M, Witucki G, Guttenberger R and Berger DP: Is there any correlation between MDR1, GST-pi-expression and CEA? Anticancer Res 20: 5139-5144, 2000.
21. Bradley G and Ling V: P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 13: 223-233, 1994.
22. Wenz F, Engling A, Schäfer J, Fruehauf S and Weber KJ: [Genetherapeutic and pharmacological modulation of radiation-induced apoptosis] Gentherapeutische und pharmokologische Modulation der bestrahlungsinduzierten Apoptose. In: [Proceedings of the 9th Symposium: Experimental and Clinical Radiation Biology] Experimentelle Strahlenbiologie und Klinische Strahlenbiologie (Beck-Bornholdt HP, Baumann M, Raabe A and Peterson C, eds). Hamburg, pp. 115, 2000.
23. Ruth AC and Roninson IB: Effects of the multidrug transporter P-glycoprotein on cellular responses to ionizing radiation. Cancer Res 60: 2576-2578, 2000.
24. Weissenberger C, Fiebig HH, Guttenberger R, Hinkelbein W and Frommhold H: Correlation between expression of drug resistance, tumour markers and radioresistance. In: 3rd Balkan Congress of Oncology (Antypas G, ed). pp. 141-146, 2000.
25. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG and Somerfield MR: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1865-1878, 2001.
26. Persijn JP and Korsten CB: The development of a radioimmuno-assay for carcino-embryonic antigen with some applications. Clinical evaluation of carcino-embryonic antigen, I. J Clin Chem Clin Biochem 14: 377-387, 1976.
27. Qiu H, Sirivongs P, Rothenberger M, Rothenberger DA and Garcia-Aguilar J: Molecular prognostic factors in rectal cancer treated by radiation and surgery. Dis Colon Rectum 43: 451-459, 2000.
28. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229, 1997.
29. Rodel F, Hoffmann J, Grabenbauer GG, Papadopoulos T, Weiss C, Gunther K, Schick C, Sauer R and Rodel C: High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 178: 426-435, 2002.